Literature DB >> 17678432

Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine.

Rodolfo Viotti1, Carlos Vigliano.   

Abstract

No randomized clinical trials regarding the etiological treatment of chronic Chagas disease can be found in the medical literature. However, other 'evidence' sustaining the use of anti-Trypanosoma cruzi drugs for adult individuals with Chagas disease will be analyzed along with the limitations in evaluating the treatment efficacy. Today, the hypothesis of T. cruzi persistence in the target organs giving rise to the chronic inflammatory response is sustained. In addition, several experimental, pathological, nonrandomized clinical studies and studies based on the response or serological evolution (besides the clinical experience) demonstrate the role of T. cruzi in the pathogenesis of the chronic stage and the efficacy of etiological treatment to reduce the titers of antibodies and the progression of chronic Chagas heart disease. All of this supports the recommendation of treatment for every patient diagnosed with Chagas disease. The interpretation of this sum of evidence is not considered from the perspective of evidence-based medicine.

Entities:  

Mesh:

Year:  2007        PMID: 17678432     DOI: 10.1586/14787210.5.4.717

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  21 in total

1.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.

Authors:  Julio A Urbina; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2015-12       Impact factor: 5.191

Review 3.  Parasitic infections and myositis.

Authors:  Samar N El-Beshbishi; Nairmen N Ahmed; Samar H Mostafa; Goman A El-Ganainy
Journal:  Parasitol Res       Date:  2011-09-01       Impact factor: 2.289

4.  Methodological advances in drug discovery for Chagas disease.

Authors:  Juan M Bustamante; Rick L Tarleton
Journal:  Expert Opin Drug Discov       Date:  2011-06       Impact factor: 6.098

5.  Emerging parasitic infections in transplantation.

Authors:  Roberta Lattes; Laura Linares; Marcelo Radisic
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

6.  Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi.

Authors:  Arlete Rita Penitente; Ana Luísa Junqueira Leite; Guilherme de Paula Costa; Deena Shrestha; Aline Luciano Horta; Antônio J Natali; Clóvis A Neves; Andre Talvani
Journal:  Am J Trop Med Hyg       Date:  2015-09-08       Impact factor: 2.345

Review 7.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

8.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

9.  Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment.

Authors:  Paola Carolina Bazán; María Silvina Lo Presti; Héctor Walter Rivarola; María Fernanda Triquell; Ricardo Fretes; Alicia Ruth Fernández; Julio Enders; Patricia Paglini-Oliva
Journal:  Parasitol Res       Date:  2008-05-31       Impact factor: 2.289

10.  Towards a paradigm shift in the treatment of chronic Chagas disease.

Authors:  R Viotti; B Alarcón de Noya; T Araujo-Jorge; M J Grijalva; F Guhl; M C López; J M Ramsey; I Ribeiro; A G Schijman; S Sosa-Estani; F Torrico; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.